

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 July 2003 (03.07.2003)

PCT

(10) International Publication Number
WO 2003/053349 A3

(51) International Patent Classification⁷: A61K 38/12

(21) International Application Number:
PCT/US2002/039926

(22) International Filing Date:
13 December 2002 (13.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/344,080 20 December 2001 (20.12.2001) US
60/382,103 20 May 2002 (20.05.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
[US/US]; P.O. Box 4000, Route 206 and Provinceline
Road, Princeton, NJ 08543-4000 (US).

Published:
— with international search report

(72) Inventors: CAMPBELL, Jeffrey, Allen; 525 Alpine
Drive, Cheshire, CT 06410 (US). GOOD, Andrew,
Charles; 52 High Hill Road, Wallingford, CT 06492 (US).

(88) Date of publication of the international search report:
15 January 2004

(74) Agents: DUBOFF, Samuel et al.; Bristol-Myers Squibb
Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2003/053349 A3

(54) Title: INHIBITORS OF HEPATITIS C VIRUS

(57) Abstract: The present invention relates to macrocyclic compounds, methods for making these compounds, pharmaceutical compositions and the therapeutic or prophylactic use of these compounds by administering said compounds to mammals to prevent or treat hepatitis C virus (HCV) infection.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/39926

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/12

US CL : 530/317

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/317; 435/5; 435/6. A61K 38/05, 38/06; A61P 31/14; C07K 5/08, 5/078

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Please See Continuation SheetElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Internal Structure Search (CAS-STN Registry, HCAPLUS, CAOLD, USPATFULL, MARPAT, MARPATPREV); Internal Patent Search (EAST-USPAT, US-PGPUB, EPO, JPO, DERWENT); Internal Inventor Search (PALM).**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00/059929 A1 (BOEHRINGER INGELHEIM (CANADA) LTD., 12 October 2000 (12.20.00), claim 1 (compound, 1st -C- bound to cyclopropyl), claim 54 (method of inhibiting HCV NS3 protease), claim 55 (pharmaceutical composition and carrier), claim 62 (medicament for treatment of a mammal with HCV)[also disclosed on specification pages 2, 20, and 22].	1-14
Y	US 6,323,180 B1 (LLINAS-BRUNET et al.) 27 November 2001 (27.11.01), claims (teaches use of sulfonyl compound in treatment of HCV NS3 protease inhibition, along with use of cyclopropyl).	1,2,3,9,11



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

07 April 2003 (07.04.2003)

Date of mailing of the international search report

14 AUG 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Maury Audet

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

PCT/US02/39926

Continuation of B. FIELDS SEARCHED Item 2:

Structure search: macrocyclic peptide of formula I and II, R2, R3, R4, and Q. R1 (i.e. cyclopropyl), attached to -SOO, was not searched as -SOO functional group [attached to core peptide (-cyclopropyl-CO-NH-)] was not found among structures searched.

Term search: macrocyclic, peptide, cyclopropyl, carrier, pharmaceutical, composition, "HCV NS3 protease", HCV, NS3 protease, inhibitor, treatment.